Oliver Langer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4334247/publications.pdf

Version: 2024-02-01

157 papers	4,734 citations	81900 39 h-index	128289 60 g-index
159 all docs	159 docs citations	159 times ranked	4349 citing authors

#	Article	IF	Citations
1	Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 175-185.	4.3	14
2	PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats. Journal of Controlled Release, 2022, 342, 44-52.	9.9	11
3	Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin. Clinical Pharmacokinetics, 2022, , 1.	3.5	5
4	Pharmacokinetic Imaging Using 99mTc-Mebrofenin to Untangle the Pattern of Hepatocyte Transporter Disruptions Induced by Endotoxemia in Rats. Pharmaceuticals, 2022, 15, 392.	3.8	2
5	Strategic, feasibility, economic, and cultural aspects of phase 0 approaches. Clinical and Translational Science, 2022, 15, 1355-1379.	3.1	6
6	Use of PET Imaging to Assess the Efficacy of Thiethylperazine to Stimulate Cerebral MRP1 Transport Activity in Wild-Type and APP/PS1-21 Mice. International Journal of Molecular Sciences, 2022, 23, 6514.	4.1	2
7	Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats. Journal of Controlled Release, 2022, 349, 109-117.	9.9	5
8	Complete inhibition of ABCB1 and ABCG2 at the bloodâ€“brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [¹¹C]erlotinib. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1634-1646.	4.3	17
9	Influence of Cation Transporters (OCTs and MATEs) on the Renal and Hepatobiliary Disposition of [11C]Metoclopramide in Mice. Pharmaceutical Research, 2021, 38, 127-140.	3.5	1
10	Repurposing 99mTc-Mebrofenin as a Probe for Molecular Imaging of Hepatocyte Transporters. Journal of Nuclear Medicine, 2021, 62, 1043-1047.	5.0	4
11	Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates. Pharmaceutics, 2021, 13, 918.	4.5	2
12	ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure. Frontiers in Pharmacology, 2021, 12, 698966.	3.5	6
13	Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice. Pharmaceutics, 2021, 13, 1286.	4.5	7
14	Influence of ABC transporters on the excretion of ciprofloxacin assessed with PET imaging in mice. European Journal of Pharmaceutical Sciences, 2021, 163, 105854.	4.0	7
15	Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide. Molecular Imaging and Biology, 2021, 23, 180-185.	2.6	0
16	Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology and Therapeutics, 2021, 109, 754-761.	4.7	13
17	Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 150-162.	4.3	20
18	Measurement of cerebral ABCC1 transport activity in wild-type and APP/PS1-21 mice with positron emission tomography. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 954-965.	4.3	14

#	Article	IF	Citations
19	In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2026-2035.	6.4	3
20	Pharmacokinetic Imaging with Radiolabeled Molecularly Targeted Anticancer Drugs. Journal of Nuclear Medicine, 2020, 61, 306-306.	5.0	0
21	Imaging P-Glycoprotein Induction at the Bloodâ€“Brain Barrier of a Î²-Amyloidosis Mouse Model with ¹¹C-Metoclopramide PET. Journal of Nuclear Medicine, 2020, 61, 1050-1057.	5.0	21
22	Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [11C]Tariquidar and PET in Humans and Mice. Molecular Pharmaceutics, 2020, 17, 316-326.	4.6	15
23	Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model. International Journal of Molecular Sciences, 2020, 21, 8245.	4.1	4
24	Tobacco Smoke and Inhaled Drugs Alter Expression and Activity of Multidrug Resistance-Associated Protein-1 (MRP1) in Human Distal Lung Epithelial Cells in vitro. Frontiers in Bioengineering and Biotechnology, 2020, 8, 1030.	4.1	12
25	Phase 0/microdosing approaches: time for mainstream application in drug development?. Nature Reviews Drug Discovery, 2020, 19, 801-818.	46.4	55
26	Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [99mTc]mebrofenin Imaging in Rats. Pharmaceutics, 2020, 12, 486.	4.5	7
27	Use of imaging to assess the activity of hepatic transporters. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 149-164.	3.3	17
28	Assessing the Activity of Multidrug Resistanceâ€“Associated Protein 1 at the Lung Epithelial Barrier. Journal of Nuclear Medicine, 2020, 61, 1650-1657.	5.0	16
29	Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model. Scientific Reports, 2019, 9, 16310.	3.3	42
30	Inhibition of ABCB1 and ABCG2 at the Mouse Bloodâ€“Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [¹¹C]erlotinib. Molecular Pharmaceutics, 2019, 16, 1282-1293.	4.6	20
31	Generation and Characterization of anAbcc1Humanized Mouse Model (hABCC1^{flx/flx}) with Knockout Capability. Molecular Pharmacology, 2019, 96, 138-147.	2.3	4
32	Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography. AAPS Journal, 2019, 21, 61.	4.4	14
33	Imaging Pâ€Glycoprotein Function at the Bloodâ€“Brain Barrier as a Determinant of the Variability in Response to Central Nervous System Drugs. Clinical Pharmacology and Therapeutics, 2019, 105, 1061-1064.	4.7	25
34	PET imaging of the mouse brain reveals a dynamic regulation of SERT density in a chronic stress model. Translational Psychiatry, 2019, 9, 80.	4.8	7
35	Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate ¹¹C-Metoclopramide Assessed with PET Imaging in Humans. Journal of Nuclear Medicine, 2019, 60, 985-991.	5.0	38
36	Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[11C]Methylpurine in Mice. Molecular Imaging and Biology, 2019, 21, 306-316.	2.6	15

#	Article	IF	Citations
37	A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Bloodâ€“Brain Barrier. Journal of Nuclear Medicine, 2019, 60, 486-491.	5.0	25
38	Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. EJNMMI Research, 2019, 9, 110.	2.5	2
39	Pitfalls and solutions of the fully-automated radiosynthesis of [11C]metoclopramide. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 31.	3.9	7
40	Investigation of Transporter-Mediated Drug-Drug Interactions Using PET/MRI. , 2019, , 117-133.		0
41	Imaging techniques to study drug transporter function in vivo. , 2018, 189, 104-122.		57
42	Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 599-606.	1.6	18
43	Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice. European Journal of Pharmaceutical Sciences, 2018, 115, 212-222.	4.0	4
44	Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates. Drug Delivery and Translational Research, 2018, 8, 536-542.	5.8	7
45	Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Clinical Pharmacology and Therapeutics, 2018, 104, 139-147.	4.7	43
46	PET-MR and SPECT-MR multimodality probes: Development and challenges. Theranostics, 2018, 8, 6210-6232.	10.0	59
47	Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4. EJNMMI Radiopharmacy and Chemistry, 2018, 3, 8.	3.9	10
48	EGFR is required for FOSâ€dependent bone tumor development via RSK2/CREB signaling. EMBO Molecular Medicine, 2018, 10, .	6.9	24
49	Humanization of the bloodâ€“brain barrier transporter ABCB1 in mice disrupts genomic locus â€” lessons from three unsuccessful approaches. European Journal of Microbiology and Immunology, 2018, 8, 78-86.	2.8	2
50	Liver Imaging and Hepatobiliary Contrast Media. Contrast Media and Molecular Imaging, 2018, 2018, 1-2.	0.8	1
51	Molar activity â€“ The keystone in 11C-radiochemistry: An explorative study using the gas phase method. Nuclear Medicine and Biology, 2018, 67, 21-26.	0.6	4
52	Effect of Rifampicin on the Distribution of [¹¹C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. Molecular Pharmaceutics, 2018, 15, 4589-4598.	4.6	17
53	Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats. EJNMMI Research, 2018, 8, 81.	2.5	8
54	P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of ¹¹C-Metoclopramide Across the Bloodâ€“Brain Barrier: A PET Study on Nonhuman Primates. Journal of Nuclear Medicine, 2018, 59, 1609-1615.	5.0	39

#	Article	IF	Citations
55	Effect of Pâ€glycoprotein inhibition at the bloodâ€“brain barrier on brain distribution of (R)â€[¹¹C]verapamil in elderly vs. young subjects. British Journal of Clinical Pharmacology, 2017, 83, 1991-1999.	2.4	28
56	A Prediction Method for P-glycoproteinâ€“Mediated Drugâ€“Drug Interactions at the Human Bloodâ€“Brain Barrier From Blood Concentrationâ€“Time Profiles, Validated With PET Data. Journal of Pharmaceutical Sciences, 2017, 106, 2780-2786.	3.3	4
57	PET probes for imaging pancreatic islet cells. Clinical and Translational Imaging, 2017, 5, 507-523.	2.1	5
58	Hepatocyte-Specific Deletion of EGFR in Mice Reduces Hepatic Abcg2 Transport Activity Measured by [11C]erlotinib and Positron Emission Tomography. Drug Metabolism and Disposition, 2017, 45, 1093-1100.	3.3	11
59	Expression of endogenous mouse APP modulates Î²-amyloid deposition in hAPP-transgenic mice. Acta Neuropathologica Communications, 2017, 5, 49.	5.2	21
60	Assessment of P-Glycoprotein Transport Activity at the Human Bloodâ€“Retina Barrier with (R)â€¹¹C-Verapamil PET. Journal of Nuclear Medicine, 2017, 58, 678-681.	5.0	23
61	On the applicability of [18F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapy. Nuclear Medicine and Biology, 2017, 44, 83-89.	0.6	14
62	Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Bloodâ€“Brain Barrier: A PET Study on Nonhuman Primates. Journal of Nuclear Medicine, 2017, 58, 117-122.	5.0	43
63	Reproducibility of Quantitative Brain Imaging Using a PET-Only and a Combined PET/MR System. Frontiers in Neuroscience, 2017, 11, 396.	2.8	8
64	[11 C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice. Nuclear Medicine and Biology, 2017, 52, 7-15.	0.6	6
65	32nd International Austrian Winter Symposium. EJNMMI Research, 2016, 6, 32.	2.5	0
66	Synthesis and preclinical characterization of 1-(6â€²-deoxy-6â€²-[18 F]fluoro-Î²- d) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 Td (-allofu assess tumor hypoxia. Bioorganic and Medicinal Chemistry, 2016, 24, 5326-5339.	3.0	13
67	Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [18F]FBPA in human and mouse tumour cell lines. Applied Radiation and Isotopes, 2016, 118, 67-72.	1.5	12
68	Use of PET Imaging to Evaluate Transporterâ€Mediated Drugâ€Drug Interactions. Journal of Clinical Pharmacology, 2016, 56, S143-56.	2.0	48
69	Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Bloodâ€“Brain Barrier. Clinical Pharmacology and Therapeutics, 2016, 100, 131-141.	4.7	50
70	Whole-Body Distribution and Radiation Dosimetry of ¹¹C-Elacridar and ¹¹C-Tariquidar in Humans. Journal of Nuclear Medicine, 2016, 57, 1265-1268.	5.0	11
71	Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [18F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. Journal of Pharmaceutical Sciences, 2016, 105, 106-112.	3.3	5
72	Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model. Molecular Pharmacology, 2016, 89, 492-504.	2.3	23

#	Article	IF	Citations
73	Tools in Clinical Pharmacology: Imaging Techniques. , 2016, , 139-150.		1
74	[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 741-749.	6.4	5
75	Factors Governing P-Glycoprotein-Mediated Drugâ€“Drug Interactions at the Bloodâ€“Brain Barrier Measured with Positron Emission Tomography. Molecular Pharmaceutics, 2015, 12, 3214-3225.	4.6	39
76	[18F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent bloodâ€“brain barrier. Nuclear Medicine and Biology, 2015, 42, 585-589.	0.6	2
77	Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography. Journal of Medicinal Chemistry, 2015, 58, 6058-6080.	6.4	18
78	Automated electrophilic radiosynthesis of [18F]FBPA using a modified nucleophilic GE TRACERlab FXFDG. Applied Radiation and Isotopes, 2015, 104, 124-127.	1.5	9
79	Approaching Complete Inhibition of P-Glycoprotein at the Human Bloodâ€“Brain Barrier: An (R)-[¹¹C]Verapamil PET Study. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 743-746.	4.3	74
80	Development and performance test of an online blood sampling system for determination of the arterial input function in rats. EJNMMI Physics, 2015, 2, 1.	2.7	22
81	Automated radiosynthesis of [18F]ciprofloxacin. Applied Radiation and Isotopes, 2015, 99, 133-137.	1.5	5
82	Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of ¹¹C-Erlotinib. Journal of Nuclear Medicine, 2015, 56, 1930-1936.	5.0	52
83	Role of (Drug) Transporters in Imaging in Health and Disease. Drug Metabolism and Disposition, 2014, 42, 2007-2015.	3.3	11
84	Alzheimerâ€™s and ABC transporters â€" new opportunities for diagnostics and treatment. Neurobiology of Disease, 2014, 72, 54-60.	4.4	66
85	In vivo P-glycoprotein function before and after epilepsy surgery. Neurology, 2014, 83, 1326-1331.	1.1	37
86	Using Positron Emission Tomography to Study Transporter-Mediated Drugâ€“Drug Interactions in Tissues. Clinical Pharmacology and Therapeutics, 2014, 96, 206-213.	4.7	31
87	(R)-[11C]verapamil is selectively transported by murine and human P-glycoprotein at the bloodâ€“brain barrier, and not by MRP1 and BCRP. Nuclear Medicine and Biology, 2013, 40, 873-878.	0.6	67
88	Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study. Drug Metabolism and Disposition, 2013, 41, 754-762.	3.3	79
89	Complementary Techniques: Positron Emission Tomography. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 269-282.	0.6	0
90	Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats. Nuclear Medicine and Biology, 2013, 40, 755-763.	0.6	15

#	Article	IF	Citations
91	P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurology, The, 2013, 12, 777-785.	10.2	155
92	Factors That Limit Positron Emission Tomography Imaging of P-Glycoprotein Density at the Bloodâ€“Brain Barrier. Molecular Pharmaceutics, 2013, 10, 2222-2229.	4.6	18
93	Interaction of ¹¹C-Tariquidar and ¹¹C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Bloodâ€“Brain Barrier. Journal of Nuclear Medicine, 2013, 54, 1181-1187.	5.0	45
94	Radioligands targeting Pâ€glycoprotein and other drug efflux proteins at the bloodâ€“brain barrier. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 68-77.	1.0	45
95	A Novel PET Protocol for Visualization of Breast Cancer Resistance Protein Function at the Bloodâ€“Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 2002-2011.	4.3	46
96	Bloodâ€“brain barrier P-glycoprotein function in Alzheimer's disease. Brain, 2012, 135, 181-189.	7.6	252
97	Interaction of HM30181 with P-glycoprotein at the murine bloodâ€“brain barrier assessed with positron emission tomography. European Journal of Pharmacology, 2012, 696, 18-27.	3.5	9
98	Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [11C]MC113. Nuclear Medicine and Biology, 2012, 39, 1219-1225.	0.6	17
99	Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Bloodâ€“Brain Barrier: A Comparison With Rat Data. Clinical Pharmacology and Therapeutics, 2012, 91, 227-233.	4.7	108
100	Pharmacokinetic modeling of P-glycoprotein function at the rat and human bloodâ€“brain barriers studied with (R)-[11C]verapamil positron emission tomography. EJNMMI Research, 2012, 2, 58.	2.5	16
101	The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the bloodâ€“brain barrier: A positron emission tomography study. Epilepsy Research, 2012, 100, 93-103.	1.6	12
102	A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 149-159.	6.4	23
103	A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with 14C- and 11C-Labelled Verapamil. Clinical Pharmacokinetics, 2011, 50, 111-120.	3.5	31
104	PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo. Current Drug Metabolism, 2011, 12, 774-792.	1.2	59
105	Approaches using molecular imaging technology â€" use of PET in clinical microdose studies. Advanced Drug Delivery Reviews, 2011, 63, 539-546.	13.7	102
106	Radiosynthesis and Assessment of Ocular Pharmacokinetics of 124I-Labeled Chitosan in Rabbits Using Small-Animal PET. Molecular Imaging and Biology, 2011, 13, 222-226.	2.6	19
107	Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorganic and Medicinal Chemistry, 2011, 19, 2190-2198.	3.0	30
108	Gastric Cancer Growth Control by BEZ235In VivoDoes Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake. Clinical Cancer Research, 2011, 17, 5322-5332.	7.0	33

#	Article	IF	Citations
109	A Novel Positron Emission Tomography Imaging Protocol Identifies Seizure-Induced Regional Overactivity of P-Glycoprotein at the Blood-Brain Barrier. Journal of Neuroscience, 2011, 31, 8803-8811.	3.6	58
110	Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 942-953.	6.4	102
111	Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorganic and Medicinal Chemistry, 2010, 18, 5489-5497.	3.0	73
112	Small-animal PET evaluation of [11C]MC113 as a PET tracer for P-glycoprotein. BMC Pharmacology, 2010, 10, .	0.4	0
113	Dose-response assessment of tariquidar for inhibition of P-glycoprotein at the human blood-brain barrier using (R)-[11C]verapamil PET. BMC Pharmacology, 2010, 10, .	0.4	0
114	Assessment of Regional Differences in Tariquidar-Induced P-Glycoprotein Modulation at the Human Bloodâ€“Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 510-515.	4.3	34
115	Imaging of P-glycoprotein Function and Expression to Elucidate Mechanisms of Pharmacoresistance in Epilepsy. Current Topics in Medicinal Chemistry, 2010, 10, 1785-1791.	2.1	40
116	Evaluation of [11C]elacridar and [11C]tariquidar in transporter knockout mice using small-animal PET. NeuroImage, 2010, 52, S25.	4.2	3
117	Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. Nuclear Medicine and Biology, 2010, 37, 637-644.	1.9	12
118	Tools in clinical pharmacology - imaging techniques. , 2010, , 193-203.		0
119	A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Bloodâ€“Brain Barrier with (R)-¹¹C-Verapamil and PET. Journal of Nuclear Medicine, 2009, 50, 1954-1961.	5.0	99
120	Limitations of Small Animal PET Imaging with [18F]FDDNP and FDG for Quantitative Studies in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Molecular Imaging and Biology, 2009, 11, 236-240.	2.6	87
121	Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. European Journal of Clinical Pharmacology, 2009, 65, 941-946.	1.9	65
122	Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Bloodâ^'Brain Barrier. Journal of Medicinal Chemistry, 2009, 52, 6073-6082.	6.4	71
123	New ultrasensitive detection technologies and techniques for use in microdosing studies. Bioanalysis, 2009, 1, 357-366.	1.5	27
124	Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 116-123.	6.4	39
125	Microdosing Studies in Humans. Drugs in R and D, 2008, 9, 73-81.	2.2	42
126	Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Bloodâ€“Brain Barrier Studied with (R)-¹¹C-Verapamil and PET. Journal of Nuclear Medicine, 2008, 49, 1328-1335.	5.0	104

#	Article	IF	Citations
127	Positron emission tomography for use in microdosing studies. Current Opinion in Drug Discovery & Development, 2008, 11, 104-10.	1.9	12
128	Pharmacoresistance in Epilepsy: A Pilot PET Study with the P-Glycoprotein Substrate R -[11 C]verapamil. Epilepsia, 2007, 48, 1774-1784.	5.1	119
129	A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimerâ€™s disease. Clinical Pharmacology and Therapeutics, 2006, 80, 216-227.	4.7	53
130	Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS Journal, 2006, 8, E263-E271.	4.4	70
131	Synthesis of fluorine-18-labelled 5- and 6-fluoro-2-pyridinamine. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 345-356.	1.0	13
132	Microdialysis Versus Other Techniques for the Clinical Assessment of In Vivo Tissue Drug Distribution. AAPS Journal, 2006, 08, E263.	4.4	5
133	Influence of functional haplotypes in the drug transporter gene on central nervous system drug distribution in humans. Clinical Pharmacology and Therapeutics, 2005, 78, 182-190.	4.7	64
134	Synthesis of 1,1â€² [11C]-methylene-di-(2-naphthol) ([11C]ST1859) for PET studies in humans. Journal of Labelled Compounds and Radiopharmaceuticals, 2005, 48, 577-587.	1.0	12
135	In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 143-150.	6.4	77
136	Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. Journal of Nuclear Medicine, 2005, 46, 1835-41.	5.0	35
137	[18 F]Ciprofloxacin, a New Positron Emission Tomography Tracer for Noninvasive Assessment of the Tissue Distribution and Pharmacokinetics of Ciprofloxacin in Humans. Antimicrobial Agents and Chemotherapy, 2004, 48, 3850-3857.	3.2	54
138	Biological evaluation of 2â€²-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nuclear Medicine and Biology, 2004, 31, 291-295.	0.6	43
139	Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, 611C9RGH-1756 in the monkey brain. Neurochemistry International, 2004, 45, 609-617.	3.8	31
140	A novel electrophilic synthesis and evaluation of medium specific radioactivity (1R,2S)-4-[18F]fluorometaraminol, a tracer for the assessment of cardiac sympathetic nerve integrity with PET. Nuclear Medicine and Biology, 2004, 31, 103-110.	0.6	21
141	Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs. Current Drug Metabolism, 2004, 5, 463-481.	1.2	70
142	Preparation of 4-[11C]methylmetaraminol, a potential PET tracer for assessment of myocardial sympathetic innervation. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 55-65.	1.0	18
143	A general method for the fluorine-18 labelling of fluoroquinolone antibiotics. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 715-727.	1.0	10
144	Comparison of three different purification methods for the routine preparation of [11C] Metomidate. Applied Radiation and Isotopes, 2003, 59, 125-128.	1.5	8

#	Article	IF	Citations
145	Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. Nuclear Medicine and Biology, 2003, 30, 285-291.	0.6	123
146	PET and SPET tracers for mapping the cardiac nervous system. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 416-434.	6.4	66
147	Synthesis of high-specific-radioactivity 4- and 6-[18F]fluorometaraminol- PET tracers for the adrenergic nervous system of the heart. Bioorganic and Medicinal Chemistry, 2001, 9, 677-694.	3.0	40
148	Improved specific radioactivity of the PET radioligand [11C]FLB 457 by use of the GE medical systems PETtrace MeI microlab. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 331-338.	1.0	49
149	Radiochemical labelling of the dopamine D3 receptor ligand RGH-1756. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 1069-1074.	1.0	10
150	Preparation of [18F]Î²-CFT-FP and [11C]Î²-CFT-FP, selective radioligands for visualisation of the dopamine transporter using positron emission tomography (PET). Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 1235-1244.	1.0	19
151	High specific radioactivity (1R,2S)-4-[18F]fluorometaraminol: a PET radiotracer for mapping sympathetic nerves of the heart. Nuclear Medicine and Biology, 2000, 27, 233-238.	0.6	17
152	Carbon-11 pb-12: an attempt to visualize the dopamine d4 receptor in the primate brain with positron emission tomography. Nuclear Medicine and Biology, 2000, 27, 707-714.	0.6	24
153	Absolute quantitation of iodine-123 epidepride kinetics using single-photon emission tomography: comparison with carbon-11 epidepride and positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1580-1588.	6.4	20
154	Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate. Journal of Labelled Compounds and Radiopharmaceuticals, 1999, 42, 1183-1193.	1.0	105
155	Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors. Nuclear Medicine and Biology, 1999, 26, 509-518.	0.6	20
156	Preparation of 4- and 6-[76Br] bromometaraminol, two potential radiotracers for the study of the myocardial norepinephrine neuronal reuptake system with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 1997, 39, 803-816.	1.0	8
157	Some new methods for the synthesis of cardiac neurotransmission PET radiotracers. Nuclear Medicine and Biology, 1995, 22, 1037-1043.	0.6	4